• IN EDITION MEDICUS WAS PUBLISHED

    MULTIDISCIPLINARY APPROACH to Oesophageal and gastric cancer

     

    EDITOR: RADKA OBERMANNOVA
    ASSOCIATE EDITORS: FLORIAN LORDICK, LUBOS PETRUZELKA

    This book aims at highlighting the present and very dynamic development in the field of pper GI cancers. Oesophageal and gastric cancer are diseases with poor prognosis. Looking back to ous efforts to treat these serious malignancies have been dated already to the ancient periods. The introductory chapter of this issue is therefore dedicated to history of gastric cancer that is tightly connected to history of development of surgical techniques. Surgery remains the basic cornerstone of the treatment of localized oesophageal and gastric cancer and chapters attributed to surgery delineate the sustained development either in classical surgical techniques but also an implementation of new technologies, especially robotic surgery into clinical practice.

    Price: 474 CZK (19EUR) - (40% discount),  Order: info@currentmedia.cz
     

    MORE INFORMATION 

    Obrázek

     

Actual articles

Cabozantinib treatment – case report

04/2020 MUDr. Igor Richter, Ph.D.; doc. MUDr. Josef Dvořák, Ph.D.
The Czech Republic is the world leader in the incidence of kidney cancer worldwide. Approximately 70% of renal cancers are clear cell renal, which is associated with von Hippel-Lindau (VHL) gene dysfunction. This disorder is associated with the accumulation of hypoxia-inducible factor (HIF), which results in similar metabolic events as in hypoxia. The result is the induction of vascular endothelial growth factor (VEGF) with subsequent stimulation of angiogenesis. Inhibition of angiogenesis is therefore a rational basis for therapy. According to the current reimbursement decree, sunitinib and pazopanib inhibitors are of the greatest importance in the first-line treatment of metastatic clear cell renal cell carcinoma of the vascular endothelial growth factor receptor (VEGFR). In most patients, however, the disease gradually progresses. The newer VEGFR inhibitor cabozantinib, which also acts on other signaling pathways (MET, AXL), can currently be indicated in the second line. This fact makes it possible to overcome resistance to previous VEGFR inhibitors. This is evidenced by the results of the METEOR study, where cabozantinib showed a significant prolongation of progression-free survival, overall survival and response to previous treatment with VEGFR inhibitors compared to everolimus. We started using cabozantinib in clinical practice at our workplace in 2018. Below we describe the case report of a patient treated with cabozantinib.
ENTIRE ARTICLE

Metastatic colorectal cancer – case report

04/2020 MUDr. Stanislav Batko
Metastatic colorectal cancer is still a challenge for physicians. Various modalities are used in its treatment, including chemotherapy, targeted treatment and local methods of intervention, including surgical resection, radiofrequency ablation, radiotherapy, chemoand radioembolization. There are relatively loose recommendations for systemic treatment, the involvement of other treatment modalities is defined much more freely, as well as applied in practice. A proactive approach combining the maximum use of systemic treatment, together with the agile application of local methods, can lead to a significant benefit in the overall survival of patients through generally available methods.
ENTIRE ARTICLE

The role of alectinib in the treatment of advanced non‑small cell lung cancer

04/2020 MUDr. Daniel Krejčí; MUDr. Jana Krejčí; MUDr. Petr Opálka, CSc., MBA; MUDr. Bc. Petr Zůna; doc. MUDr. Norbert Pauk, CSc.
Despite a small percentage of these patients, the issue of patients with a positive mutation in the anaplastic lymphoma kinase (ALK) gene is highly debated. Alectinib demonstrated a statistically significant prolongation of progression-free time and an excellent therapeutic and preventive effect in the central nervous system in phase III ALEX, J-ALEX and ALUR studies.1-3 At the time of writing, alectinib is fully reimbursed in first-line treatment even after crizotinib failure.4
ENTIRE ARTICLE